Healthy Clinical Trial
Official title:
PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [F-18]FBR
The purpose of this protocol is to measure peripheral benzodiazepine receptors in the brain using positron emission tomography (PET) and compare the imaging results between patients and healthy people.
Objective
In endemic regions neurocysticercosis is the most common cause of adult acquired epilepsy and
thus an important public health problem. The disease is caused by infection with the larval
form of the tapeworm, Taenia solium. Although neurocysticercosis is common only in many
developing regions, an increased number of patients are diagnosed in developed countries
mostly due to immigration of infected individuals.
The peripheral benzodiazepine receptor (PBR) can be a clinically useful marker to detect
neuroinflammation because activated microglia in inflammatory areas expresses high levels of
PBR. PBR has been imaged with positron emission tomography (PET) using [(11)
C]1-(2-chlorophenyl-N-methylpropyl)-3-isoquinoline carboxamide (PK11195), which provides low
levels of specific signal. Recently we developed a new ligand,
N-fluroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline ([(18)F]FBR), which showed much
greater specific signals than [(11) C]PK11195 in non-human primates.
The major objective of this protocol is to assess the utility of [(18) F]FBR PET to detect
neuroinflammation in patients with neurocysticercosis.
A secondary objective is to study whether some healthy subjects do not show binding of
[(18)F]FBR by performing whole body imaging using [18F]FBR and binding assays using blood
cells. In other protocols using a PET ligand with similar structure, [(11)C]PBR28,
approximately 8% of subjects (9/~ 118 ) did not show binding. In protocols 07-N-0035 and
08-M-0158, we compared binding of [11C]PBR28 and [(11)C]PK 11195 in approximately ten healthy
subjects including five who did not show binding of [(11)C]PBR28 in prior whole body imaging.
We found differences in organs with regard to sensitivity to the phenomenon of non-binding.
In the non-binders, PBR28 showed no binding in all five organs with high PBR density.
However, PK 11195 showed significantly reduced binding in only two organs with PBR. We now
wish to determine whether PBR06 is more similar to PBR28 or to PK 11195 in terms of the
non-binding phenomenon. In the current protocol, in addition to whole body imaging using
[(18)F]FBR, we will do in vitro binding assays using blood cells as another tissue to examine
the effect of non-binding.
Study population
For [(18)F]FBR brain scans, ten patients will be recruited and clinically followed under
protocol 85-I-0127, Treatment of Cysticercosis including Neurocysticercosis with Praziquantel
or Albendazole (PI: Theodore E. Nash, MD, NIAID). Fifteen healthy subjects will be recruited.
For whole body scan using [(18)F]FBR, additional 30 healthy subjects will be recruited.
Therefore, total accrual numbers are 10 patients with neurocysticercosis and 45 healthy
subjects (15 for brain [(18)F]FBR and 30 for whole body [(18)F]FBR scans.
Design
Ten patients with neurocysticercosis and 15 age-matched healthy subjects will have brain PET
scans. In addition, we will also perform a whole body PET scan on 30 healthy subjects to
study the radiation-absorbed doses and study whether some healthy subjects do not show
binding of [(18)F]FBR. Patients will have up to three [(18)F]FBR PET scans during the
follow-up and the treatment under 85-I-0127, typically a few weeks apart.
Outcome measures
<TAB>
In brain PET scans, [(18)F]FBR binding will be compared with clinical symptoms and MRI
findings. In addition, the binding will be compared between patients and age-matched control
subjects. We have calculated radiation absorbed doses in approximately seven healthy subjects
who showed normal distribution (i.e., binders) of activity in organs. If we found subjects
who appear to have no binding to [(18)F]FBR, we will calculate radiation-absorbed doses of
the non-binders.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT00001844 -
Study of New Magnetic Resonance Methods
|
||
Completed |
NCT03160261 -
Effect of Exenatide on Cortisol Secretion
|
Phase 4 | |
Completed |
NCT03662100 -
A Study of Two Formulations of LY3074828 in Healthy Participants
|
Phase 1 | |
Recruiting |
NCT02875301 -
Investigating Gains in Neurocognition in an Intervention Trial of Exercise
|
Phase 3 | |
Recruiting |
NCT03656952 -
A Study to Evaluate the PF-06700841 Effect on QTc Interval in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT03670082 -
Study With Lu AF35700 in Healthy Men and Women in Fasting and Fed State
|
Phase 1 | |
Completed |
NCT03056846 -
Probiotics on Stress-associated Gastrointestinal Function in University Students
|
N/A | |
Completed |
NCT03203824 -
The Effects of Dark Chocolate (70% Cacao) on EEG Brain Waves in Vigorously Active Individuals
|
N/A | |
Recruiting |
NCT03114839 -
Effect of Lactobacillus Casei Shirota on the Small Intestinal Microbiota (ROBIN)
|
N/A | |
Completed |
NCT03224702 -
First-in-Human Trial of Anti-ADAMTS-5 Nanobody in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT03259464 -
This Study Tests BI 685509 in Healthy Chinese and Japanese Men; the Study Tests How Different Doses of BI 685509 Are Taken up in the Body and How Well They Are Tolerated
|
Phase 1 | |
Completed |
NCT03309566 -
Bioequivalence Study of Two Formulatiosns With the Asscociaton of Efavirenz, Emtricitabine and Tenofovir
|
Phase 4 | |
Completed |
NCT00526916 -
PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [C-11]PBR28
|
Phase 1 | |
Recruiting |
NCT03713268 -
Intraoperative OCT Guidance of Intraocular Surgery II
|
||
Completed |
NCT03373162 -
Functional Effects of Botox on the Brain Using MRS and fMRI
|
Phase 4 | |
Active, not recruiting |
NCT02509494 -
Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo During Implementation of Stages 1 and 2
|
Phase 3 | |
Terminated |
NCT02555085 -
Single Ascending Doses of BIIB063 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT03125018 -
Accuracy of SpO2 for Noninvasive Pulse Oximeter Sensor (LNCS ADTX)
|
N/A | |
Completed |
NCT03124901 -
Accuracy of Noninvasive Pulse Oximeter Measurement of Hemoglobin for Rainbow DCI Sensor
|
N/A |